The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
Chugai Pharmaceutical and Hiroshima University spinoff TWOCELLS said on November 29 that surgery was performed on the first patient in a PIII study of a regenerative cellular medicine for chondrogenesis in the knee (development code: gMSC1) conducted by the startup.…
To read the full story
Related Article
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Chugai, TWOCELLS End Knee Chondrogenesis Cell Therapy Deal
April 14, 2023
- Chugai/TWOCELLS Complete PIII Enrollment for Knee Chondrogenesis Cell Medicine
October 28, 2021
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…